Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...
Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...
Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...
M health care spinoff Solventum is selling its purification business to Thermo Fisher Scientific for $4.1 billion in cash to ...
Shares of Solventum Corp. SOLV shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for ...
Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...
Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One research ...
Mizuho raised the firm’s price target on Solventum (SOLV) to $82 from $70 and keeps a Neutral rating on the shares following the Q4 report. The ...
Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Thermo Fisher Scientific agreed to pay about $4.1 billion in cash to acquire Solventum’s purification and filtration business ...
Nelson Peltz’s Trian Fund Management plans to push Solventum (SOLV) to separate more of its businesses after the company sold its filtration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results